BioLife Q2 rev $40.5M (+30% YoY); net loss $72.6M on $69.9M impairment; guides FY22 rev $160-166M

BIOLIFE SOLUTIONS INC

2022-Q2 EPS reported -$1.89 revenue$76,752,000

Q2 2022 revenue $40.5M, up 30% YoY; organic growth 44%; biopreservation media revenue up 46%.
GAAP net loss $72.6M ($1.71 loss per share) vs net income $7.9M ($0.19 EPS) in Q2 2021; includes $69.9M non-cash impairment charge.
Adjusted EBITDA positive $1.5M in Q2 2022 vs $3.7M in Q2 2021; adjusted gross margin 36% vs 43% prior year.
Full-year 2022 revenue guidance updated to $160M-$166M (34-39% growth) with positive adjusted EBITDA expected.
Cash and marketable securities $46.6M as of June 30, 2022; down $12.9M from March 31 due to working capital and capex.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.